Tecentriq Hybreza (atezolizumab/ hyaluronidase-tqjs)

Adult Dosing .

Dosage forms:  INJ: 1875 mg/30,000 units per 15 mL

Special Note

[drug name clarification]

Info: nonproprietary name = atezolizumab/hyaluronidase-tqjs

[equivalency or interchangeability info]

Info: not interchangeable with IV atezolizumab; do not substitute on a mg to mg basis

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

non-small cell lung CA

[stage II-IIIA PD-L1-expressing disease, adjuvant tx]

Dose: 1875 mg/30,000 units SC q3wk for up to 1y; Start: after resection and platinum-based chemo

[metastatic high PD-L1-expressing disease, first-line tx]

Dose: 1875 mg/30,000 units SC q3wk; Info: for patients with no EGFR or ALK genomic tumor aberrations

[metastatic nonsquamous disease, first-line tx]

Dose: 1875 mg/30,000 units SC q3wk; Info: for patients with no EGFR or ALK genomic tumor aberrations; part of multi-drug chemo regimen

[metastatic progressive disease]

Dose: 1875 mg/30,000 units SC q3wk; Info: for patients with disease progression on or after platinum-containing chemo

small cell lung CA, extensive-stage

[first-line induction tx]

Dose: 1875 mg/30,000 units SC q3wk; Info: part of multi-drug chemo regimen

[maintenance tx]

Dose: 1875 mg/30,000 units SC q3wk; Info: for patients without disease progression after first-line induction tx; use with lurbinectedin

hepatocellular CA, unresectable or metastatic

[1875 mg/30,000 units SC q3wk]

Info: use with bevacizumab

melanoma, unresectable or metastatic

[1875 mg/30,000 units SC q3wk]

Start: after one 28-day cycle of cobimetinib and vemurafenib; Info: for patients with BRAF V600 mutation; use with cobimetinib and vemurafenib

alveolar soft part sarcoma, unresectable or metastatic

[1875 mg/30,000 units SC q3wk]

renal dosing

[see below]

eGFR >30: no adjustment; eGFR <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-3x ULN or AST >ULN: no adjustment; bilirubin >3x ULN: not defined

Peds Dosing .

Dosage forms:  INJ: 1875 mg/30,000 units per 15 mL

Special Note

[drug name clarification]

Info: nonproprietary name = atezolizumab/hyaluronidase-tqjs

[equivalency or interchangeability info]

Info: not interchangeable with IV atezolizumab; do not substitute on a mg to mg basis

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

alveolar soft part sarcoma, unresectable or metastatic

[12 yo and older, >40 kg]

Dose: 1875 mg/30,000 units SC q3wk

renal dosing

[see below]

eGFR >30: no adjustment; eGFR <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-3x ULN or AST >ULN: no adjustment; bilirubin >3x ULN: not defined